- Home
- LVTX vs HOOK Comparison
LVTX vs HOOK Comparison
Compare LVTX & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- HOOK
- Stock Information
- Founded
- LVTX 2016
- HOOK 2011
- Country
- LVTX Netherlands
- HOOK United States
- Employees
- LVTX N/A
- HOOK N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- LVTX Health Care
- HOOK Health Care
- Exchange
- LVTX Nasdaq
- HOOK Nasdaq
- Market Cap
- LVTX 27.9M
- HOOK 24.2M
- IPO Year
- LVTX 2021
- HOOK 2019
- Fundamental
- Price
- LVTX $1.02
- HOOK $1.86
- Analyst Decision
- LVTX Buy
- HOOK Buy
- Analyst Count
- LVTX 3
- HOOK 4
- Target Price
- LVTX $3.33
- HOOK $23.00
- AVG Volume (30 Days)
- LVTX 208.1K
- HOOK 103.0K
- Earning Date
- LVTX 12-10-2024
- HOOK 11-14-2024
- Dividend Yield
- LVTX N/A
- HOOK N/A
- EPS Growth
- LVTX N/A
- HOOK N/A
- EPS
- LVTX N/A
- HOOK N/A
- Revenue
- LVTX $7,345,000.00
- HOOK $49,999,000.00
- Revenue This Year
- LVTX N/A
- HOOK $147.52
- Revenue Next Year
- LVTX N/A
- HOOK N/A
- P/E Ratio
- LVTX N/A
- HOOK N/A
- Revenue Growth
- LVTX N/A
- HOOK 143.30
- 52 Week Low
- LVTX $0.88
- HOOK $1.75
- 52 Week High
- LVTX $6.47
- HOOK $10.50
- Technical
- Relative Strength Index (RSI)
- LVTX 37.42
- HOOK 32.63
- Support Level
- LVTX $0.95
- HOOK $1.83
- Resistance Level
- LVTX $1.04
- HOOK $2.28
- Average True Range (ATR)
- LVTX 0.08
- HOOK 0.18
- MACD
- LVTX 0.03
- HOOK 0.03
- Stochastic Oscillator
- LVTX 58.16
- HOOK 20.75
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.